The MarketWatch News Department was not involved in the creation of this content. -- A new pooled analysis of the FIBRONEER(TM)-IPF and FIBRONEER(TM)-ILD trials resulted in a nominally significant ...
New FIBRONEER results were presented by Boehringer Ingelheim at this year’s European Respiratory Society (ERS) International ...
Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...
GRI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of the small molecule RAR-βɣ dual agonist, GRI-0621, to treat idiopathic pulmonary fibrosis (IPF).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback